These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35091749)

  • 1. Pharmacogenetics of Between-Individual Variability in Plasma Clearance of Bedaquiline and Clofazimine in South Africa.
    Haas DW; Abdelwahab MT; van Beek SW; Baker P; Maartens G; Bradford Y; Ritchie MD; Wasserman S; Meintjes G; Beeri K; Gandhi NR; Svensson EM; Denti P; Brust JCM
    J Infect Dis; 2022 Aug; 226(1):147-156. PubMed ID: 35091749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis.
    Nimmo C; Millard J; van Dorp L; Brien K; Moodley S; Wolf A; Grant AD; Padayatchi N; Pym AS; Balloux F; O'Donnell M
    Lancet Microbe; 2020 Aug; 1(4):e165-e174. PubMed ID: 32803174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study.
    Ismail NA; Omar SV; Moultrie H; Bhyat Z; Conradie F; Enwerem M; Ferreira H; Hughes J; Joseph L; Kock Y; Letsaolo V; Maartens G; Meintjes G; Ngcamu D; Okozi N; Padanilam X; Reuter A; Romero R; Schaaf S; Te Riele J; Variava E; van der Meulen M; Ismail F; Ndjeka N
    Lancet Infect Dis; 2022 Apr; 22(4):496-506. PubMed ID: 34780706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis.
    Almeida D; Ioerger T; Tyagi S; Li SY; Mdluli K; Andries K; Grosset J; Sacchettini J; Nuermberger E
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4590-9. PubMed ID: 27185800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clofazimine Exposure
    Ismail N; Peters RPH; Ismail NA; Omar SV
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30642938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline.
    Villellas C; Coeck N; Meehan CJ; Lounis N; de Jong B; Rigouts L; Andries K
    J Antimicrob Chemother; 2017 Mar; 72(3):684-690. PubMed ID: 28031270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis.
    Xu J; Wang B; Hu M; Huo F; Guo S; Jing W; Nuermberger E; Lu Y
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence of Canonical and Noncanonical Genomic Variants following
    Ismail N; Dippenaar A; Warren RM; Peters RPH; Omar SV
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0136822. PubMed ID: 36892309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis.
    Sonnenkalb L; Carter JJ; Spitaleri A; Iqbal Z; Hunt M; Malone KM; Utpatel C; Cirillo DM; Rodrigues C; Nilgiriwala KS; Fowler PW; Merker M; Niemann S;
    Lancet Microbe; 2023 May; 4(5):e358-e368. PubMed ID: 37003285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sub-MIC levels of bedaquiline and clofazimine can select
    Villellas C; Stevenaert F; Remmerie B; Andries K
    Antimicrob Agents Chemother; 2024 Apr; 68(4):e0127523. PubMed ID: 38470194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First report of whole-genome analysis of an extensively drug-resistant Mycobacterium tuberculosis clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda.
    Kabahita JM; Kabugo J; Kakooza F; Adam I; Guido O; Byabajungu H; Namutebi J; Namaganda MM; Lutaaya P; Otim J; Kakembo FE; Kanyerezi S; Nabisubi P; Sserwadda I; Kasule GW; Nakato H; Musisi K; Oola D; Joloba ML; Mboowa G
    Antimicrob Resist Infect Control; 2022 May; 11(1):68. PubMed ID: 35550202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort study.
    Derendinger B; Dippenaar A; de Vos M; Huo S; Alberts R; Tadokera R; Limberis J; Sirgel F; Dolby T; Spies C; Reuter A; Folkerts M; Allender C; Lemmer D; Van Rie A; Gagneux S; Rigouts L; Te Riele J; Dheda K; Engelthaler DM; Warren R; Metcalfe J; Cox H; Theron G
    Lancet Microbe; 2023 Dec; 4(12):e972-e982. PubMed ID: 37931638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquisition of Cross-Resistance to Bedaquiline and Clofazimine following Treatment for Tuberculosis in Pakistan.
    Ghodousi A; Rizvi AH; Baloch AQ; Ghafoor A; Khanzada FM; Qadir M; Borroni E; Trovato A; Tahseen S; Cirillo DM
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bedaquiline-Resistant Tuberculosis: Dark Clouds on the Horizon.
    Andres S; Merker M; Heyckendorf J; Kalsdorf B; Rumetshofer R; Indra A; Hofmann-Thiel S; Hoffmann H; Lange C; Niemann S; Maurer FP
    Am J Respir Crit Care Med; 2020 Jun; 201(12):1564-1568. PubMed ID: 32053752
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluating the effect of clofazimine against Mycobacterium tuberculosis given alone or in combination with pretomanid, bedaquiline or linezolid.
    Kim S; Louie A; Drusano GL; Almoslem M; Kim S; Myrick J; Nole J; Duncanson B; Peloquin CA; Scanga CA; Yamada W; Neely M; Schmidt S
    Int J Antimicrob Agents; 2022 Feb; 59(2):106509. PubMed ID: 34958863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro approaches for generation of Mycobacterium tuberculosis mutants resistant to bedaquiline, clofazimine or linezolid and identification of associated genetic variants.
    Ismail N; Omar SV; Ismail NA; Peters RPH
    J Microbiol Methods; 2018 Oct; 153():1-9. PubMed ID: 30165087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.
    Kadura S; King N; Nakhoul M; Zhu H; Theron G; Köser CU; Farhat M
    J Antimicrob Chemother; 2020 Aug; 75(8):2031-2043. PubMed ID: 32361756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in the MAB_2299c TetR Regulator Confer Cross-Resistance to Clofazimine and Bedaquiline in
    Richard M; Gutiérrez AV; Viljoen A; Rodriguez-Rincon D; Roquet-Baneres F; Blaise M; Everall I; Parkhill J; Floto RA; Kremer L
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30323043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis.
    Liu Y; Gao J; Du J; Shu W; Wang L; Wang Y; Xue Z; Li L; Xu S; Pang Y
    Int J Infect Dis; 2021 Jan; 102():392-396. PubMed ID: 33130209
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Schulthess B; Akdoğan Kittana FN; Hömke R; Sander P
    Antimicrob Agents Chemother; 2022 May; 66(5):e0234621. PubMed ID: 35420492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.